… Currently, limited data on tyrosine kinase inhibitors as … operable stage II-IIIA NSCLC with
epidermal growth factor receptor … Patients were treated with preoperative gefitinib (250 mg once …

… Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor
(EGFR) … Of note, a recent phase 2 study failed to exhibit the superiority of osimertinib, a third-…

… growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) over platinum-based regimens
… a randomized phase II study, NEJ005, that compared the concurrent use of gefitinib and …

… a large family of EGFR tyrosine kinase inhibitors (TKI) were … in a phase III randomized study
compared with gefitinib, a first-… In the ARCHER 1042 [Citation29] phase II trial, the effect on …

… vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, plus … Epidermal growth
factor receptor … placebo-controlled phase 2 study 26 on advanced NSCLC after two lines of …

… A meta-analysis that summarized direct analysis between gefitinib and erlotinib showed no
… (6 studies; 303 patients) did not differ between treatments with erlotinib or gefitinib, as these …

… /without Gefitinib Trial In this phase II study, 60 patients with resected NSCLC bearing EGFR
mutations, exon 19 deletion or L858R, were enrolled [29]. Participants with stage IIIA were …

… stage IIIB/IV NSCLC and an epidermal growth factor receptor (… tyrosine kinase inhibitors
(TKIs) are the standard initial treatment for patients with EGFR mutation-positive NSCLC; gefitinib…

… to the first-generation TKI erlotinib or gefitinib in the FLAURA study. In a post hoc analysis,
a … A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as …

… EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and … Epidermal growth factor receptor
(EGFR) tyrosine kinase … resistance, 30 a recent Phase 2 study found that pembrolizumab …